[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004108898A3 - Agents de transfection - Google Patents

Agents de transfection Download PDF

Info

Publication number
WO2004108898A3
WO2004108898A3 PCT/US2004/017612 US2004017612W WO2004108898A3 WO 2004108898 A3 WO2004108898 A3 WO 2004108898A3 US 2004017612 W US2004017612 W US 2004017612W WO 2004108898 A3 WO2004108898 A3 WO 2004108898A3
Authority
WO
WIPO (PCT)
Prior art keywords
agents
genes
compositions
cell
methods
Prior art date
Application number
PCT/US2004/017612
Other languages
English (en)
Other versions
WO2004108898A2 (fr
Inventor
Robert Connor
Joseph Mcauliffe
Original Assignee
Canji Inc
Robert Connor
Joseph Mcauliffe
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/455,215 external-priority patent/US20040014709A1/en
Application filed by Canji Inc, Robert Connor, Joseph Mcauliffe filed Critical Canji Inc
Priority to AU2004245995A priority Critical patent/AU2004245995A1/en
Priority to EP04754260A priority patent/EP1629085A2/fr
Priority to CA002528136A priority patent/CA2528136A1/fr
Priority to JP2006515161A priority patent/JP2007526219A/ja
Priority claimed from PCT/US2004/017788 external-priority patent/WO2004108088A2/fr
Publication of WO2004108898A2 publication Critical patent/WO2004108898A2/fr
Publication of WO2004108898A3 publication Critical patent/WO2004108898A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des composés, des compositions et des procédés qui favorisent le transfert d'un agent dans une cellule. Les agents peuvent comprendre des polypeptides, des polynucléotides tels que des gènes et des acides nucléiques antisens, et d'autres molécules. Dans certains modes de réalisation, les agents sont des agents de modulation qui peuvent moduler une activité ou une fonction cellulaire lorsqu'ils sont introduits dans la cellule. Les composés, compositions et procédés sont utilisés pour introduire des agents tels que des gènes dans des cellules individuelles, et dans des cellules présentes sous forme de tissu ou d'organe.
PCT/US2004/017612 2003-06-04 2004-06-04 Agents de transfection WO2004108898A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2004245995A AU2004245995A1 (en) 2003-06-04 2004-06-04 Transfection agents
EP04754260A EP1629085A2 (fr) 2003-06-04 2004-06-04 Agents de transfection
CA002528136A CA2528136A1 (fr) 2003-06-04 2004-06-04 Agents de transfection
JP2006515161A JP2007526219A (ja) 2003-06-04 2004-06-04 トランスフェクション薬剤

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47592603P 2003-06-04 2003-06-04
US10/455,215 US20040014709A1 (en) 1996-01-08 2003-06-04 Methods and compositions for interferon therapy
US10/455,215 2003-06-04
US60/475,926 2003-06-04
USPCT/US04/17788 2004-06-04
PCT/US2004/017788 WO2004108088A2 (fr) 2003-06-04 2004-06-04 Procedes et compositions pour la therapie a l'interferon

Publications (2)

Publication Number Publication Date
WO2004108898A2 WO2004108898A2 (fr) 2004-12-16
WO2004108898A3 true WO2004108898A3 (fr) 2006-04-27

Family

ID=33514684

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/017612 WO2004108898A2 (fr) 2003-06-04 2004-06-04 Agents de transfection

Country Status (2)

Country Link
JP (1) JP2007262081A (fr)
WO (1) WO2004108898A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
TR201910060T4 (tr) 2001-12-20 2019-07-22 Merck Sharp & Dohme SYN3 bileşimleri ve yöntemleri.
EP1940775A2 (fr) * 2005-08-11 2008-07-09 University of Massachusetts Procedes et compositions pour l'apport efficace d'agents therapeutiques dans des cellules et des animaux

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells

Also Published As

Publication number Publication date
JP2007262081A (ja) 2007-10-11
WO2004108898A2 (fr) 2004-12-16

Similar Documents

Publication Publication Date Title
WO2003087367A3 (fr) Moyens et procedes pour l'inhibition specifique de genes dans les cellules et le tissu du systeme nerveux central et/ou de l'oeil
EP1507005A3 (fr) Modulation antisens de l'expression du gène BCL-X
WO2002036743A3 (fr) Modulation antisens de l'expression de calreticuline
CA2323086A1 (fr) Regulation de l'expression genique endogene dans des cellules au moyen de proteines a doigts de zinc
WO2004029219A3 (fr) Interference arn basee sur les cellules, et procedes et compositions s'y rapportant
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
EP1709195A4 (fr) Formulations de transfection cellulaire de petits arn interferents, compositions correspondantes et procedes de production et d'utilisation
WO2004108899A3 (fr) Micro-reseau pni et son utilisation
WO2005082341A3 (fr) Agents non peptidyl a activite de type phsp20 et utilisations correspondantes
WO2003093469A3 (fr) Procedes d'administration de molecules d'acides nucleiques dans des cellules et evaluation associee
WO1998000532A3 (fr) Oligonucleotides provenant des regions non traduites de genes constitutifs, et procede d'utilisation de ces oligonucleotides afin de moduler la croissance cellulaire
ZA971158B (en) Nucleic acid constructs for the cell cycle-regulated expression of genes, cells containing such constructs and their use for preparing drugs.
WO2005023305A3 (fr) Modulation de l'activite cellulaire au moyen d'un agent diminuant le taux de cholesterol au sein d'une cellule
WO2005040388A3 (fr) Systemes d'expression eucaryotes a compartiments multiples
MXPA01008137A (es) Secuencias antisensa antitumorales dirigidas en contra de los componentes r1 y r2 de la reductasa de ribonucleotido.
EP1224202A4 (fr) Modulation antisens de l'expression de kinase liee aux integrines
WO2001023541A3 (fr) Compositions et methodes pouvant modifier l'expression genique
WO2006076628A3 (fr) Compositions renfermant des sequences promoteurs et procedes d'utilisation
EP1212456A4 (fr) Modulation antisens de l'expression de shp-2
WO2005054439A3 (fr) Manipulation genetique hereditaire via l'arnsi dans des plantes
WO2004108898A3 (fr) Agents de transfection
WO2001083513A3 (fr) Modulation antisens de l'inhibiteur de l'expression de la fixation 1 a l'adn
WO2000036113A3 (fr) Methodes permettant d'ameliorer les chances de survie d'une greffe par modulation de l'activite heme oxygenase
EP1144690A4 (fr) Modulation antisens de l'expression d'un inhibiteur cellulaire d'apoptose-2
WO2004010956A3 (fr) Modulation par antisens d'expression de lar

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480019510.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006515161

Country of ref document: JP

Ref document number: PA/a/2005/012978

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2528136

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 543969

Country of ref document: NZ

Ref document number: 2004754260

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004245995

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004245995

Country of ref document: AU

Date of ref document: 20040604

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004245995

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004754260

Country of ref document: EP